Celldex Therapeutics(CLDX) - 2024 Q2 - Quarterly Results

EXHIBIT 99.1 Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update Phase 3 CSU studies initiated July 2024 Positive topline Phase 2 CIndU 12 week data reported July 2024 supporting Phase 3 advancement 52 week Phase 2 CSU data and full 12 week Phase 2 CIndU data to be reported 2H 2024 Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to start YE 2024 Celldex's first bispecific for inflammatory diseases, CDX-622, to enter the clinic this year HAMPTON, N.J., Aug ...